Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Common Equity (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Common Equity for 5 consecutive years, with $114.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 55.51% to $114.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.3 million through Dec 2025, down 55.51% year-over-year, with the annual reading at $114.3 million for FY2025, 55.51% down from the prior year.
  • Common Equity hit $114.3 million in Q4 2025 for ARS Pharmaceuticals, down from $147.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $368.5 million in Q1 2021 to a low of -$50.2 million in Q3 2022.
  • Historically, Common Equity has averaged $185.9 million across 5 years, with a median of $226.4 million in 2024.
  • Biggest YoY gain for Common Equity was 972.7% in 2022; the steepest drop was 115.1% in 2022.
  • Year by year, Common Equity stood at -$31.3 million in 2021, then skyrocketed by 972.7% to $272.9 million in 2022, then fell by 15.44% to $230.8 million in 2023, then grew by 11.28% to $256.8 million in 2024, then plummeted by 55.51% to $114.3 million in 2025.
  • Business Quant data shows Common Equity for SPRY at $114.3 million in Q4 2025, $147.7 million in Q3 2025, and $192.3 million in Q2 2025.